Aurobindo Pharma Limited

rs,

(E), MUMBAI -400 051 To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804

Rs 6,407.1 crore

the quarter 5 Consolidated Financial & Business Highlights – Q3 FY23 Revenue from operations at Rs 6,407.1 crore, US revenues at US$ 365.5 Million Research & Development (R&D) spend at Rs 415.2 crore in Q3FY23,

365.5 Million

al & Business Highlights – Q3 FY23 Revenue from operations at Rs 6,407.1 crore, US revenues at US$ 365.5 Million Research & Development (R&D) spend at Rs 415.2 crore in Q3FY23, 6.5% of revenue Vs. Rs. 275.6 cror

Rs 415.2 crore

ations at Rs 6,407.1 crore, US revenues at US$ 365.5 Million Research & Development (R&D) spend at Rs 415.2 crore in Q3FY23, 6.5% of revenue Vs. Rs. 275.6 crore in Q2FY23, 4.8% of revenue EBITDA before Forex and

6.5%

, US revenues at US$ 365.5 Million Research & Development (R&D) spend at Rs 415.2 crore in Q3FY23, 6.5% of revenue Vs. Rs. 275.6 crore in Q2FY23, 4.8% of revenue EBITDA before Forex and Other income at

Rs. 275.6 crore

365.5 Million Research & Development (R&D) spend at Rs 415.2 crore in Q3FY23, 6.5% of revenue Vs. Rs. 275.6 crore in Q2FY23, 4.8% of revenue EBITDA before Forex and Other income at Rs 954.4 crore; EBITDA margin

4.8%

Development (R&D) spend at Rs 415.2 crore in Q3FY23, 6.5% of revenue Vs. Rs. 275.6 crore in Q2FY23, 4.8% of revenue EBITDA before Forex and Other income at Rs 954.4 crore; EBITDA margin is at 14.9% Ne

Rs 954.4 crore

of revenue Vs. Rs. 275.6 crore in Q2FY23, 4.8% of revenue EBITDA before Forex and Other income at Rs 954.4 crore; EBITDA margin is at 14.9% Net Profit at Rs 491.2 crore Basic & Diluted EPS is Rs 8.38 per share

14.9%

FY23, 4.8% of revenue EBITDA before Forex and Other income at Rs 954.4 crore; EBITDA margin is at 14.9% Net Profit at Rs 491.2 crore Basic & Diluted EPS is Rs 8.38 per share Net organic capex for the

Rs 491.2 crore

EBITDA before Forex and Other income at Rs 954.4 crore; EBITDA margin is at 14.9% Net Profit at Rs 491.2 crore Basic & Diluted EPS is Rs 8.38 per share Net organic capex for the quarter ~US$ 82 Million includ

Rs 8.38

at Rs 954.4 crore; EBITDA margin is at 14.9% Net Profit at Rs 491.2 crore Basic & Diluted EPS is Rs 8.38 per share Net organic capex for the quarter ~US$ 82 Million including investment of ~US$ 39 Million

82 Million

at Rs 491.2 crore Basic & Diluted EPS is Rs 8.38 per share Net organic capex for the quarter ~US$ 82 Million including investment of ~US$ 39 Million in PLI project Net cash including investments at the end